NGM Biopharmaceuticals, Inc.
NASDAQ:NGM
1.54 (USD) • At close April 4, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
| Revenue
| 4.417 | 55.333 | 77.882 | 87.368 | 103.544 | 108.665 | 77.141 | 85.589 |
| Cost of Revenue
| 2.221 | 5.984 | 7.899 | 163.972 | 129.253 | 0 | 0 | 0 |
| Gross Profit
| 2.196 | 49.349 | 69.983 | -76.604 | -25.709 | 108.665 | 77.141 | 85.589 |
| Gross Profit Ratio
| 0.497 | 0.892 | 0.899 | -0.877 | -0.248 | 1 | 1 | 1 |
| Reseach & Development Expenses
| 112.008 | 181.067 | 161.712 | 163.972 | 129.253 | 95.714 | 79.736 | 82.105 |
| General & Administrative Expenses
| 37.84 | 40.515 | 36.865 | 27.229 | 23.631 | 17.265 | 14.83 | 11.845 |
| Selling & Marketing Expenses
| -1.105 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 36.735 | 40.515 | 36.865 | 27.229 | 23.631 | 17.265 | 14.83 | 11.845 |
| Other Expenses
| -0.234 | -0.132 | -0.06 | -0.593 | -0.147 | 0.199 | -0.152 | 0.133 |
| Operating Expenses
| 148.743 | 221.582 | 198.577 | 191.201 | 152.884 | 112.979 | 94.566 | 93.95 |
| Operating Income
| -146.547 | -166.249 | -120.695 | -103.833 | -49.34 | -4.314 | -17.425 | -8.361 |
| Operating Income Ratio
| -33.178 | -3.005 | -1.55 | -1.188 | -0.477 | -0.04 | -0.226 | -0.098 |
| Total Other Income Expenses Net
| 4.172 | 3.582 | 0.36 | 1.346 | 6.545 | 3.821 | 2.206 | 1.939 |
| Income Before Tax
| -142.375 | -162.667 | -120.335 | -102.487 | -42.795 | -0.493 | -15.219 | -6.422 |
| Income Before Tax Ratio
| -32.233 | -2.94 | -1.545 | -1.173 | -0.413 | -0.005 | -0.197 | -0.075 |
| Income Tax Expense
| 0 | -3.582 | -6.509 | -8.494 | -14.297 | 3.821 | -1.06 | 0.5 |
| Net Income
| -142.375 | -159.085 | -113.826 | -93.993 | -28.498 | -0.493 | -14.159 | -6.922 |
| Net Income Ratio
| -32.233 | -2.875 | -1.462 | -1.076 | -0.275 | -0.005 | -0.184 | -0.081 |
| EPS
| -1.73 | -1.99 | -1.48 | -1.37 | -0.57 | -0.008 | -0.26 | -0.13 |
| EPS Diluted
| -1.73 | -1.99 | -1.48 | -1.37 | -0.57 | -0.008 | -0.26 | -0.13 |
| EBITDA
| -144.326 | -166.249 | -120.695 | -103.833 | -49.34 | 2.909 | -10.984 | -4.827 |
| EBITDA Ratio
| -32.675 | -3.005 | -1.55 | -1.188 | -0.477 | 0.027 | -0.142 | -0.056 |